The Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center is a multidisciplinary center of excellence dedicated to patient care, research, and education in all facets of these diseases. It is based at Weill Cornell Medicine the entity that includes Weill Cornell Medical College and the New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City.
The MPNs are a related group of blood stem cell disorders, most commonly polycythemia vera, essential thrombocythemia, primary myelofibrosis, myeloid metaplasia, and chronic myelogenous leukemia (CML), but also including chronic eosinophilias (hypereosinophilic syndromes), mast cell disorders (systemic mastocytosis), chronic neutrophilic leukemia, overlap states between MPNs and myelodysplastic syndrome (MDS), and not infrequently currently unclassifiable MPNs.
Under the leadership of Andrew I. Schafer, M.D., the Richard T. Silver MPN Center offers the most advanced, comprehensive care for patients with MPNs. It also provides for consultations, second opinions, or co-management of patients with MPNs with physicians outside Weill Cornell Medicine. Our patient care mission is anchored in the following guiding principles:
An overarching philosophy of the Richard T. Silver MPN Center is that its patient care mission cannot be independent of its educational and research missions. We proactively provide numerous educational opportunities to students, other trainees, physicians and scientists involved in MPNs locally, nationally, and internationally. Most importantly, we educate patients individually and provide educational forums for patient interest and patient advocacy groups in the MPNs.
The Richard T. Silver MPN Center is also committed to research and discovery to better understand the cause of the MPNs, their basic mechanisms of disease progression, and their complications. To that end, we have a growing program in original research in the area of MPNs. The Center’s research activities in this field range from basic laboratory investigation to patient-oriented research and clinical trials to outcomes measurements, with our work funded by federal and foundation grants as well as industry.